Document
IPR2023-00724, No. 1146 Exhibit - Exhibit 1146 KDOQI 2007 (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1146 Exhibit - Exhibit 1146 KDOQI 2007 (P.T.A.B. May. 22, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2396 Exhibit - EX2396 US Food Drug Administration, DrugsFDA, Byetta® (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2396 Exhibit - EX2396 US Food Drug Administration, DrugsFDA, Byetta® (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2380 Exhibit - EX2380 Mayo Clinic, “A1C test,” httpswwwmayoclinicorgtests procedures a1c testaboutpac 20384643, last updated Dec 1, 2022 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2380 Exhibit - EX2380 Mayo Clinic, “A1C test,” httpswwwmayoclinicorgtests procedures a1c testaboutpac 20384643, last updated Dec 1, 2022 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2379 Exhibit - EX2379 Novo Nordisk, “Managing your diabetes,” httpswwwmynovoinsulincomdiabetes educationmanaging diabeteshtml, last updated Dec 2022 (P.T.A.B. Ja...
Cite Document
IPR2023-00724, No. 2379 Exhibit - EX2379 Novo Nordisk, “Managing your diabetes,” httpswwwmynovoinsulincomdiabetes educationmanaging diabeteshtml, last updated Dec 2022 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2014 Exhibit - EX2014 Weeda, E, et al, “Medication adherence to injectable glucagon like peptide 1 GLP 1 receptor agonists dosed once weekly vs once daily in patients wit...
Cite Document
IPR2023-00724, No. 2014 Exhibit - EX2014 Weeda, E, et al, “Medication adherence to injectable glucagon like peptide 1 GLP 1 receptor agonists dosed once weekly vs once daily in patients with type 2
+ More Snippets
Document
IPR2023-00724, No. 2420 Exhibit - EX2420 Bydureon® BCISE™ Prescribing Information rev Oct 2017 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2420 Exhibit - EX2420 Bydureon® BCISE™ Prescribing Information rev Oct 2017 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2093 Exhibit - EX2093 Davies, MJ, et al, Cardiovascular outcomes trials a paradigm shift in the current management of type 2 diabetes, Cardiovasc Diabetol, 21144 2022 (P...
Cite Document
IPR2023-00724, No. 2093 Exhibit - EX2093 Davies, MJ, et al, Cardiovascular outcomes trials a paradigm shift in the current management of type 2 diabetes, Cardiovasc Diabetol, 21144 2022 (P.T.A.B. Ja
+ More Snippets
Document
IPR2023-00724, No. 2485 Exhibit - EX2485 US Food Drug Administration, DrugsFDA, Actos (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2485 Exhibit - EX2485 US Food Drug Administration, DrugsFDA, Actos (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2050-2 Exhibit - EX2050 Declaration of Christine B Jensen, MD, PhD {REDACTED (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2050-2 Exhibit - EX2050 Declaration of Christine B Jensen, MD, PhD {REDACTED (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2481 Exhibit - EX2481 FDA Approves Ozempic semaglutide for Cardiovascular Risk Reduction in Adults with Type 2 Diabetes and Known Heart Disease, httpswwwdrugscom...
Cite Document
IPR2023-00724, No. 2481 Exhibit - EX2481 FDA Approves Ozempic semaglutide for Cardiovascular Risk Reduction in Adults with Type 2 Diabetes and Known Heart Disease, httpswwwdrugscomnewdrugsfda approv
+ More Snippets
Document
IPR2023-00724, No. 2078 Exhibit - EX2078 Blüher, M et al, Dose response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagonGLP 1 receptor agonist, compared with pl...
Cite Document
IPR2023-00724, No. 2078 Exhibit - EX2078 Blüher, M et al, Dose response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagonGLP 1 receptor agonist, compared with placebo and ope
+ More Snippets
Document
IPR2023-00724, No. 2066 Exhibit - EX2066 Kim, K, et al, “Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms,” J Clin Pharmaco...
Cite Document
IPR2023-00724, No. 2066 Exhibit - EX2066 Kim, K, et al, “Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms,” J Clin Pharmacol, Vol44, 1083
+ More Snippets
Document
IPR2023-00724, No. 2448 Exhibit - EX2448 Xigduo® XR Prescribing Information rev July 2017 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2448 Exhibit - EX2448 Xigduo® XR Prescribing Information rev July 2017 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2407 Exhibit - EX2407 Victoza® Prescribing Information rev Nov 2020 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2407 Exhibit - EX2407 Victoza® Prescribing Information rev Nov 2020 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2354 Exhibit - EX2354 Centers for Disease Control and Prevention, “Gestational Diabetes,” httpswwwcdcgovdiabetesbasicsgestationalhtml, last reviewed Dec 30, 2022 (P....
Cite Document
IPR2023-00724, No. 2354 Exhibit - EX2354 Centers for Disease Control and Prevention, “Gestational Diabetes,” httpswwwcdcgovdiabetesbasicsgestationalhtml, last reviewed Dec 30, 2022 (P.T.A.B. Jan. 17
+ More Snippets